Welcome to our dedicated page for Scilex Holding Co SEC filings (Ticker: SCLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scilex Holding Company (SCLX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 8-K, registration statements, proxy materials and other key documents filed with the U.S. Securities and Exchange Commission. Scilex is an emerging growth company focused on non-opioid pain management products and related pipeline candidates, and its filings give detailed insight into corporate actions, financing structures and strategic agreements.
For investors tracking Scilex’s capital structure, recent Form 8-K reports describe warrant inducement agreements, exercises of existing warrants, issuance of new unregistered warrants, and the terms of non-recourse loan and securities pledge agreements with The St. James Bank & Trust Company Ltd. These filings outline interest rates tied to the 12-month Secured Overnight Financing Rate, maturity dates, pledged collateral (including Scilex and Datavault AI shares), events of default, and lender remedies.
Filings also document Scilex’s Datavault AI transactions, including a Securities Purchase Agreement for Datavault common stock and a pre-funded warrant, and a License Agreement granting Scilex a worldwide, exclusive license to Datavault patents and know-how for biotech, biopharma, genetic, diagnostic and data-related markets. The associated 8-Ks summarize consideration, royalty structures, milestones and termination conditions.
Scilex’s registration statements, such as its S-1 filing, and proxy statements (DEF 14A) provide further detail on equity incentive plans, option repricing proposals, voting rights for common and preferred stock, and governance matters. These documents complement the company’s periodic reports by explaining how management structures compensation and seeks shareholder approvals for key actions.
On Stock Titan, AI-powered tools can help interpret lengthy filings by highlighting material agreements, financial obligations, equity issuances, and risk disclosures. Users can quickly locate information on warrant terms, loan covenants, Datavault-related agreements, and other items that shape Scilex’s financial profile and strategic direction, without manually parsing every page of each filing.
Scilex Holding Company entered into a binding term sheet with Datavault AI Inc. for a proposed cash contribution and revenue participation arrangement tied to Datavault’s planned Quantum-Ready Edge Network in about 100 U.S. cities.
Scilex expects to make an upfront cash contribution of $120,000,000, paid in multiple closings with the final closing no later than December 31, 2026. In return, Datavault would pay Scilex 30% of Network Revenues until payments total $250,000,000, then 15% until combined payments reach $1,200,000,000, and 5% of Network Revenues for the remaining lifetime of the GPUs purchased with the upfront funds. The arrangement remains subject to negotiation and execution of definitive agreements, satisfaction of customary closing conditions, and achievement of specified operational and financial milestones, and may ultimately not be completed.
Scilex Holding Co director and CFO Stephen Hoi Ma reported an open-market purchase of 650,000 warrants. Each warrant was bought at $0.1538 and gives the right to buy one share of common stock at an exercise price of $1.20 per share.
The warrants were acquired on April 17, 2026 and are scheduled to expire on June 18, 2029. Following this transaction, Ma holds 650,000 warrants, each exercisable for one share of Scilex common stock.
Scilex Holding Co executive Henry Ji reported mixed warrant trades. On April 16, 2026, he made an open-market purchase of 3,250,000 warrants at $0.1538 per warrant, each exercisable at $1.20 for common stock. On April 17, 2026, he sold 650,000 warrants at the same price, leaving 2,600,000 warrants held directly, expiring on June 18, 2029.
Scilex Holding Company filed a Form S-3 to register up to $500,000,000 of securities on a shelf. The shelf prospectus permits offers of common stock, preferred stock, debt securities, warrants, rights and units in one or more offerings. The document describes existing commercial products (ZTlido, ELYXYB, GLOPERBA), pipeline assets (SP-102, SP-103, SP-104), certain corporate history and governance provisions, and states proceeds are intended for working capital and general corporate purposes.
Scilex Holding Company reports on a business focused on non-opioid pain management while outlining a major shift in its balance sheet strategy toward cryptocurrencies. The company currently markets three U.S. products: ZTlido for postherpetic neuralgia, ELYXYB for acute migraine, and GLOPERBA for prophylaxis of gout flares.
Its pipeline includes SEMDEXA (SP-102) for sciatica, SP-103 for acute low back and neck pain, and SP-104 for fibromyalgia, several with FDA fast track designations or completed Phase 3 or Phase 2 studies. Scilex also plans to adopt a cryptocurrency treasury strategy emphasizing bitcoin, Ethereum, BNB, Doge and similar assets as a principal long-term reserve, using third-party custodians and advisors, and potentially raising capital specifically to expand these holdings.
Scilex Holding Company notified the SEC that it cannot file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 by the prescribed due date of March 31, 2026 because it needs additional time to finalize financial statements, including the consolidation of Vivasor Holding Company. The company anticipates filing the Form 10-K on or before April 15, 2026.
Scilex Holding Company filed a prospectus supplement registering up to 6,685,714 shares of Common Stock (aggregate of multiple tranches, including warrants and shares issuable upon exercise) as an update to prospectuses dated May 13, 2025.
The supplement attaches Current Reports on Form 8-K that disclose several corporate actions: a $20.0 million convertible note to Q Scan that converted into 140,379,226 Q Scan shares and a related agreement to purchase 193,021,436 Q Scan shares for approximately $27.5 million; elimination of the previously designated 5,000,000 Series 1 Mandatory Exchangeable Preferred Stock; and a Warrant Agreement with Oramed issuing a 100,000-warrant issuance (the "February 2026 Warrant") exercisable at an initial price of $20.00, subject to adjustment, with a 4.99% beneficial ownership cap (adjustable to 9.99% with notice) and an expiration of December 13, 2029. The supplement notes a 1-for-35 reverse stock split effective April 15, 2025 and reports last reported share and warrant prices as of February 19, 2026 of $8.01 and $0.15, respectively.
Scilex Holding Company files a prospectus supplement updating prior prospectuses and registering up to 6,685,714 shares of Common Stock and related instruments.
The supplement incorporates three Current Reports on Form 8-K dated January 29, 2026, February 2, 2026 and February 19, 2026, and attaches them to the prospectus. It discloses a $20.0 million convertible loan to Q Scan that converted into 140,379,226 Q Scan shares and a related stock purchase agreement to buy 193,021,436 Q Scan shares for approximately $27.5 million. It also describes a Warrant Agreement with Oramed that issued 100,000 warrants at an initial exercise price of $20.00 per share (floor price $8.22), exercisable through December 13, 2029, with a 4.99% beneficial ownership exercise cap (adjustable up to 9.99% with notice).